In this study, we analyzed the effect of inclusion of antithymocyte globulin (ATG) in the reduced intensity conditioning (RIC) protocol before hematopoietic SCT with HLA-identical sibling donors. Usually, we add ATG to the conditioning protocol only when using unrelated or mismatched donors, 1 but in the RIC protocol developed by Slavin et al. 2 ATG is included regardless of the donor type.
The study included 52 consecutive patients with leukemia receiving RIC and hematopoietic SCT with an HLAidentical sibling donor between April 1999 and June 2007 at the Karolinska University Hospital. Patient and donor demographics are displayed in Table 1 . All patients received conditioning with fludarabine (30 mg/m 2 for 3-5 days) in combination with orally administered BU (total dose 8 mg/kg, n ¼ 35), 2 2 Gy TBI (n ¼ 3), 3 6 Gy fractionated TBI and CY (total dose 60 mg/kg, n ¼ 11), 4 or treosulfan (14 g/m 2 Â 3, n ¼ 3). All patients, except two, given the fludarabine and BU protocol, received (n ¼ 33) ATG 1 (Genzyme, Cambridge, MA, USA), at a dose of 2 mg/kg/ day for 4 days with the last dose given on day À1.
1,2 All patients received GVHD prophylaxis with CsA and four doses of MTX. 5 During the first month, blood CsA levels were maintained at 100-150 ng/ml. We found a significantly reduced incidence of acute GVHD grades II-IV in ATG-treated patients compared with the non-ATG patients (16 vs 55%, P ¼ 0.005). No difference in chronic GVHD was seen, 57 and 54%, respectively. Clearly, this reduction of acute GVHD was an effect of ATG, as many previous studies have shown that ATG reduces the incidence of acute GVHD. 6, 7 However, in the present study, the conditioning protocols were different in the ATG-and non-ATG-treated patients, and thus a role of RIC protocols cannot be ignored. The effect of ATG on GVHD is dose-dependent. 6, 7 In this study, a total ATG dose of 8 mg/kg was used. Previously we have shown that in unrelated donor hematopoietic SCT, this dose is effective in reducing the incidence of acute GVHD. 6 A low incidence of TRM at 1 year was seen in both ATG-and non-ATG-treated patients (9 and 12%, respectively, not significant (NS)). This is important and in line with most studies evaluating RIC protocols.
The 3-year overall survival was 60 and 75% in patients with and without ATG (NS).
A drawbacks of the in vivo T-cell depletion may be a reduction of the GVL effect and an increase in relapse incidence. 6, 7 This effect is probably also dose-dependent. 6 The GVL effect is more important using RIC compared with conventional myeloablative conditioning, because the antitumor effect of the conditioning therapy is weaker. As ATG reduces GVHD and GVL, we found a trend for a higher 3-year incidence of relapse in the ATG-treated patients (48%) compared with 12% in the non-ATG group (P ¼ 0.07). This effect was apparent in patients with highrisk disease where the incidence of relapse was 62% with ATG and 13% without ATG (P ¼ 0.025). This seems logical because high-risk patients have a higher relapse risk and need a stronger antitumor effect, especially when using RIC protocols. As a consequence of the higher relapse rate, relapse-free survival (RFS) was 43% in ATG-treated patients when compared with 77% in the non-ATG group (P ¼ 0.10). In patients with high-risk disease, the corresponding numbers were 21 and 73%, respectively (P ¼ 0.04). The two patients who received BM grafts relapsed. The cell dose is generally higher in a PBSC graft compared with a BM graft. 8 Using RIC protocols, utilizing the GVL effect from the graft, the cell dose in the graft is important. A CD34 þ cell dose of more than 6 Â 10 6 /kg was associated with decreased risk of leukemic relapse according to a study from the International Bone Marrow Transplant Registry. 9 Using ATG, the number of infused T cells is lowered by in vivo T-cell depletion in a dosedependent fashion. In patients receiving ATG, an association between a nucleated cell (NC) dose o10 Â 10 8 /kg and relapse (hazard ratio 6.16, confidence interval (CI) 1.86-20.5, P ¼ 0.003) and RFS (hazard ratio 0.34, CI 0.12-0.97, P ¼ 0.045) was found. No such correlation was seen in non-ATG-treated patients. ATG-treated patients receiving an NC dose X10 Â 10 8 /kg (n ¼ 24) had a relapse incidence of 31% and RFS of 56%, when compared with 83% (P ¼ 0.003) and 17% (P ¼ 0.05) in those receiving an NC dose o10 Â 10 8 /kg (n ¼ 9) (Figures 1a and b) . The No ATG low NC dose, n =8, 88% P =0.05 ATG removes and immobilizes the T cells and probably also delays T-cell recovery because ATG is present in the patient's serum several weeks after infusion. 10 However, from the present study, it is obvious that by increasing the cell dose, and presumably by increasing the number of T-cells and other leukocytes, the decreased GVL effect caused by ATG can be abrogated. Another possibility is to give a lower ATG dose or to omit it completely. In the multivariate analysis, ATG and a low NC dose were independently associated with relapse.
In this small study, we have found that the inclusion of ATG (8 mg/kg) in the protocol reduced the incidence of acute GVHD grades II-IV, but at the price of a weaker GVL effect leading to more relapses and an inferior RFS, especially in high-risk patients. However, this effect may be abrogated by a high cell dose in the graft.
